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Ovarian carcinoma has the highest mortality rate among gynaeco-
logical malignancies. About two-thirds of patients have already
advanced disease at the time of diagnosis. Established prognostic
indicators of ovarian carcinoma currently include disease stage,
histologic grade, residual tumour volume, and response to
chemotherapy. The identification of prognostic factors that, in
association with established clinicopathologic parameters, predict
which patients are at high risk for the development of tumour
progression, is significantly helpful in better treatment and
improvement of the survival of patients with ovarian carcinoma.
Angiogenesis is an essential requirement for tumour growth and
metastasis and basically depends on the production of angiogenic
factors by host and/or tumour cells (Folkman, 1986; 1990). It has
been shown that in animal models, without angiogenesis, tumours
grow as in situ and will not expand beyond 2–3 mm in diameter
(Folkman, 1986). The importance of angiogenesis in tumour
progression has been highlighted by studies showing that the
angiogenic potential of tumours assessed by tumour microvessel
density (MVD) directly correlates with poor prognosis (Weidner
et al, 1991; Weidner and Folkman, 1996).
Various growth factors have been shown to stimulate angiogen-
esis in physiological and pathological conditions, including
neoplastic disease. Among these, vascular endothelial growth
factor (VEGF) has been shown to play a major role in the
proliferation and migration of endothelial cells, providing nourish-
ment to the growing tumours and allowing the tumour cells to
establish continuity with the host vasculature (Ferrara, 1995).
VEGF is a 34–45 kDa heparin-binding glycoprotein which was
originally identified as a hyperpermeability factor and subse-
quently found to be a potent mitogen for the endothelial cells
(Ferrara, 1995; Senger et al, 1983; Ferrara and Hanzel, 1989; Keck
et al, 1989). It induces neovascularization through its specific
receptors flk-1 (KDR) and flt-1 (Terman et al, 1992; deVries et al,
1992). By alternating splicing of mRNA, four major isoforms of
VEGF with 121, 165, 189, and 206 amino acids may be identified
(Tischer et al, 1991). These isoforms have different bioavail-
abilities due to their different heparin-binding activity. VEGF 121
does not bind heparin and is secreted as a freely soluble protein.
VEGF 165 is a basic, heparin-binding protein, abundant in many
human tissues and tumours, and is also secreted, but to a lesser
degree than the 121 isoform. The longer isoforms with 189 and
206 amino acids have a greater affinity to heparin and are incorpo-
rated in the extracellular matrix. Inhibition of VEGF activity by
neutralizing antibodies, or by the introduction of dominant nega-
tive VEGF receptors into endothelial cells of tumour-associated
blood vessels, resulted in the inhibition of tumour growth, and
tumour regression, indicating that VEGF is a principal initiator of
tumour angiogenesis (Kim et al, 1993; Millaure et al, 1994).
Recent studies have demonstrated a significant correlation
between VEGF expression and MVD in malignant tumours arising
from several organs (Ferrara, 1999). In ovarian carcinomas, VEGF
and its receptors flt-1 and flk-1 (KDR) have been detected at
mRNA and/or protein levels (Olson et al, 1994; Boocock et al,
1995; Abu-Jawdeh et al, 1996; Paley et al, 1997; Sowter et al,
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1997; Yamamoto et al, 1997; Fujimoto et al, 1998). It was found
that patients with early stage ovarian carcinoma and increased
VEGF expression had poorer prognosis (Paley et al, 1997).
Moreover, strong VEGF expression was suggested to play an
important role in the tumour progression of ovarian carcinoma
(Yamamoto et al, 1997). In these studies, no attempt has been
made to assess the relationship between VEGF expression and
MVD. Studies addressing such an interrelationship are very
limited (Nakanishi et al, 1997; Hartenbach et al, 1997; Orre and
Rogers, 1999). In one study, a significant association was found
between the MVD and VEGF expression (Nakanishi et al, 1997).
In contrast, two other studies found no correlation between MVD
and VEGF expression (Hartenbach et al, 1997; Orre and Rogers,
1999). Furthermore, studies using multivariate statistical analyses
to assess the potential prognostic value of MVD and VEGF
expression in ovarian carcinoma are rare. In a study using multi-
variate analysis in early-stage ovarian carcinomas, VEGF over-
expression was found to be the strongest independent variable
predictive of a poor survival (Paley et al, 1997). Another study
showed that only disease stage was significant prognostic factor
and VEGF expression was not an independent prognostic indicator
(Yamamoto et al, 1997). VEGF expression was also found to be
correlated significantly with disease-free survival in patients with
invasive serious ovarian carcinomas (Garzetti et al, 1999a;
1999b). Thus, the influence of VEGF expression and MVD on
prognosis and the relationship between VEGF expression and
MVD in ovarian carcinoma are still controversial.
The purpose of this study was to clarify the significance of
VEGF expression and MVD in relation to established clinico-
pathologic prognostic factors of ovarian carcinoma.
MATERIALS AND METHODS
This study is composed of 94 diagnosed patients with epithelial
ovarian tumours who underwent surgery. The representative tissue
specimens from the lesions included 64 consecutively operated
ovarian carcinomas, 13 borderline and 17 benign ovarian tumours
(Table 1). The ages of patients ranged from 21–88 years (median,
54 years). Serial 4-mm sections from the tissues were prepared. A
section from each tissue was stained with haematoxylin and eosin
to verify the tissue and confirm the diagnosis. Histological types
and grades were determined using the World Health Organization
Criteria (Serov et al, 1973), and the stage of tumours was assessed
according to the International Federation of Gynecology and
Obstetrics staging system (Peterson, 1988). All carcinoma patients
on this study received postoperative chemotherapy with various
regimens for a high-risk early stage (stage I, grade 3; stage IC; any
stage II) or advanced diseases (stages III and IV). The clinico-
pathologic characteristics of patients are shown in Table 2.
Tumour sizes ranged from 5–30 cm in greater diameter (median,
12 cm). Of the 64 ovarian carcinoma patients, 43 were alive with
no evidence of the disease, six were alive with disease, and 15
were dead of the disease at the time of analysis. The median
follow-up for all patients (n = 64) was 31 months (range, 3–120),
and for surviving patients (n = 49) was 40.5 months (range,
16–120).
Immunohistochemistry
Immunostaining for VEGF and factor VIII-related antigen
(specific for endothelial cells) was performed using the
avidin-biotin-peroxidase complex method. Endogenous peroxi-
dase was blocked in deparaffinized tissue sections by 3%
hydrogen peroxide in methanol for 20 min. After washing with
phosphate buffer saline (PBS), pH 7.4, tissue-nonspecific binding
sites were blocked by 10% normal goat serum for 20 min. The
sections were then incubated with affinity-purified rabbit poly-
clonal anti-human VEGF (Santa Cruz Biotechnology Inc, Santa
Cruz, CA, USA) at 1:100 dilution or anti-human factor VIII-
related antigen (Dako Co., Carpinteria, CA, USA) at 1:200 dilu-
tion overnight at 4°C. Anti-human VEGF antibody had been
raised against an amino-terminal peptide (amino acids 1–20) of
VEGF molecule which recognizes all splice variants of VEGF.
This antibody has been widely used and accepted for immunohis-
tochemical localization of VEGF (Boocock et al, 1995; Yamamoto
et al, 1997; Garzetti et al, 1999a; 1999b; Orre and Rogers 1999).
After washes with PBS, biotinylated anti-rabbit IgG (Vector
Laboratories, Burlingame, CA, USA) was applied followed by
washing and detection using the avidin-biotin-peroxidase complex
(Dako Co). Diamino-benzidine was used as chromogen. The
sections were counterstained briefly with Mayer’s haematoxylin,
dehydrated, and mounted. Negative controls included the use of a
nonspecific rabbit immunoglobulin as the primary antibody. As
positive control, we used sections from an adenocarcinoma of the
lung previously found to be positive for VEGF expression and
factor VIII-related antigen.
Evaluation of immunostaining and microvessel
counting
Evaluation of immunostained sections was done without knowl-
edge of the clinical status of the patients. VEGF immunostainings
were semiquantitated according to a method used by us previously
(Ghazizadeh et al, 1997). After screening the whole section and
selection of microscopic fields using a random point grid, the
mean percentage of specific brown immunostained tumour cells
for five microscopic fields at ´ 200 magnification (´ 20 objective
lens and ´ 10 ocular lens; 0.74 mm2 per field) was determined and
was assigned an arbitrary numerical score as: 0% = 0; 1–25% = 1;
26–50% = 2; 51–75% = 3; and 76–100% = 4. In addition, the mean
intensity of immunostained areas based on the arbitrary numerical
Table 1 VEGF expression and microvessel density in ovarian tumours
VEGF expression Microvessel density
Variable n Low + Neg High Low High
Adenocarcinomaa 64 31 + 2 31 26 38
Serous 29 14 + 0 15 9 20
Mucinous 12 8 + 0 4 4 8
Endometroid 5 1 + 1 3 2 3
Clear cell 18 8 + 1 9 11 7
Borderline tumour 13 7 + 4 2 4 9
Serous 2 1 + 0 1 0 2
Mucinous 11 6 + 4 1 4 7
Benign cystadenoma 17 1 + 16 0 6 11
Serous 5 0 + 5 0 2 3
Mucinous 9 1 + 8 0 2 7
Endometroid 3 0 + 3 0 2 1
The chi-square test and Fisher’s exact test were used for comparison. aVEGF
expression in adenocarcinoma vs borderline and benign tumours: P = 0.02
and P = 0.0002 respectively.198 GH Shen et al
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scores of none = 0, weak = 1, moderate = 2, and strong = 3 was
recorded. The two values obtained for each section were then
multiplied by each other to generate the semiquantitative value of
VEGF antigen per tissue (range, 0–12).
For microvessel counting, each stained slide for factor VIII-
related antigen was examined under low magnification (´ 100) to
identify the regions of highest vascular density (vascular ‘hot
spots’) within the tumour. Microvessels were counted in five
microscopic fields of highest vascular density at ´ 200 magnifica-
tion (as above). The mean microvessel count was then calculated
for each specimen, averaged between two independent observers,
and was recorded as ‘MVD’. Small vessels counted were capil-
laries, arterioles and venules, regardless of the presence or absence
of lumens (Weidner et al, 1991). Larger arteries with thick smooth
muscle walls and distended venous sinuses were excluded.
Reverse transcription polymerase chain reaction
(RT-PCR) analysis
Total RNA from ovarian tissues (one normal ovary, one serious
cystadenoma, two serous papillary, one poorly differentiated and
one mucinous adenocarcinoma of the ovary) was extracted using
the acid guanidinium thiocyanate-phenol-chloroform extraction
method. Complementary DNA was synthesized from 2 mg of total
RNA primed with oligo(dT)16 using Superscript II reverse tran-
scriptase (Gibco BRL Ltd, Rockville, MD, USA) at 37°C for 1.5 h.
Nested PCR was carried out using 1 ml of the cDNA and the
following primers (5¢–3¢) that span the variable splice region of
VEGF mRNA: (a) GCTACTGCCATCCAATCGAGACC (exon 3,
forward); (b) GTT TCTGGATTAAGGACTGTTCTGTCG (exon
8, reverse); and (c) AATCCAATTCCAAGAGGGACCGTGC
(exon 8, reverse). First-round amplification was carried out using
0.4 mmol l–1 each of primers (a) and (c) for 15 cycles (1 min at
94°C, 2 min at 62°C, and 3 min at 72°C). Then 1 ml of the first
round PCR products was used for second-round amplification with
the nested primers (a) and (b). Amplification was for 30 cycles
under the same conditions as for the first-round amplification. The
PCR product was resolved by gel eletrophoresis and visualized by
ethidium bromide staining. A glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) was used as the internal control. Using the
described primers, the expected PCR product for each VEGF
variant was calculated as: 440 bp, 572 bp, 644 bp, and 695 bp for
isoforms of 121, 165, 189, and 206 respectively.
Statistical analysis
VEGF expression and MVD in relation to various clinicopatho-
logic factors were assessed using the chi-square test and Fisher’s
exact test. Correlation between VEGF expression and MVD was
examined by Spearman rank correlation test. Cumulative survival
probabilities of the patients were calculated by the Kaplan–Meier
method and log-rank test. The results were analysed for the
endpoint of overall survival. Survival times of patients still alive
were censored with the last follow-up date. Cox proportional
hazards regression analysis was used to identify parameters that
had significant independent relation with overall survival time. All
statistical analyses were done by the SPSS statistical software
system. A probability (P) value of less than 0.05 was considered
significant.
RESULTS
VEGF expression and microvessel density
VEGF immunoreactivity was observed mainly in the cytoplasm of
tumour cells, and also frequently in stromal cells and macrophages
(Figure 1). In benign mucinous cystadenomas, epithelial cells were
mostly negative for VEGF staining, but the luteinized theca-like
Table 2 Clinicopathologic characteristics, VEGF expression and microvessel density in ovarian carcinomas
VEGF expression Microvessel density
Variable n Low + Neg High P a Low High P a
Age
≤ 60 yrs 42 23 + 2 17 0.07 18 24 0.61
> 60 yrs 22 8 + 0 14 8 14
Tumour size
≤ 10 cm 20 11 + 0 9 0.71 8 12 0.94
> 10 cm 44 20 + 2 22 18 26
Histologic type
Serous 29 14 + 0 15 0.68 9 20 0.21
Mucinous 12 8 + 0 4 4 8
Endometroid 5 1 + 1 3 2 3
Clear cell 18 8 + 1 9 11 7
Histologic grade
Low (1–2) 46 28 + 2 16 0.0004 21 25 0.19
High (3) 18 3 + 0 15 5 13
Disease stage
Low (I–II) 37 23 + 2 12 0.002 17 20 0.31
High (III–IV) 27 8 + 0 19 9 18
Patient outcome
Alive with no
evidence of disease 43 27 + 2 14 0.0002 18 25 0.77
Died or alive
with disease 21 4 + 0 17 8 13
aThe chi-square test and Fisher’s exact test were used for comparisonVEGF and MVD in ovarian carcinoma 199
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cells in the subepithelial stroma showed positive staining (Figure
1A). Negative control sections lacked immunostaining for VEGF,
while positive control sections showed moderate to strong
immunostainings for it. The median semiquantitative VEGF
expression value for ovarian carcinomas was 3 (range: 0–8) which
was designated as a cut-off limit for determining a low and nega-
tive (values 0–2) and high (values 3–8) expression. Of the 64
ovarian carcinomas, two (3%) were negative and 31 (48%) each
had low and high VEGF expressions (Figure 1 B–E). Of the 13
borderline ovarian tumours, four (31%) were negative, seven
(54%) had low and two (15%) had high VEGF expression. Of the
17 benign cystadenomas, 16 (94%) were negative, and one (6%)
had low VEGF expression (Table 1).
Factor VIII-related antigen staining was observed in the
endothelial cells lining intratumoural microvessels, however with
variable intensities (Figure 1F). The mean MVD in benign,
borderline, and malignant ovarian tumours were 38.88 ± 17.81,
37.54 ± 11.65, and 37.64 ± 16.08, respectively. The median MVD
value for ovarian carcinomas was 32 (range: 9–85), which was
designated as a cut-off limit for dividing the cases into two groups
of low (< 32) and high (³ 32) MVD for the statistical comparisons.
RT-PCR ANALYSIS
RT-PCR was used to assess the differential expression of VEGF
mRNA splice isoforms in normal ovary and a number of benign
Figure 1 Immunohistochemical staining for VEGF (A to E) and Factor VIII-related antigen (F) in ovarian tumours. (A) Benign mucinous cystadenoma showing
lack of the staining in epithelial cells and presence of weak staining in luteinized theca-like cells in the subepithelial stromal region (arrows). (B) Serous papillary,
(C) poorly differentiated serous and (D) well-differentiated mucinous cystadenocarcinomas, and (E) endometroid type adenocarcinoma, all showing moderate to
strong cytoplasmic staining in the epithelial tumours cells. (F) Distinct visualization of intratumoural microvessels. Scale bars: 100 mm.
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and malignant ovarian tumours from which frozen tissue samples
were available. PCR amplification of cDNA prepared from frozen
tissues of one normal ovary, one serous cystadenoma, two serous
papillary, one mucinous, and one poorly differentiated adenocarci-
noma of the ovary showed the expression of four bands of 440,
572, 644, and 695 bps corresponding to VEGF isoforms of 121,
165, 189 and 206 respectively (Figure 2). In normal ovary, the
predominant isoforms were VPF/VEGF 165 and 121 respectively,
with the lack of isoform 206. In cystadenoma and carcinoma of the
ovary, all four isoforms were detected, however with an occasional
lack of the longest isoform 206 in case of carcinoma (Figure 2,
case No. 3). The predominant isoforms were, however, VEGF 121,
165, and 189 in that order.
Clinicopathologic correlations of VEGF expression and
microvessel density
A high VEGF expression was significantly associated with ovarian
carcinomas as compared to benign (P = 0.0002) or borderline
(P = 0.02) ovarian tumours (Table 1). No significant difference
was found between the low and negative vs high VEGF expres-
sions and patient age, tumour size, and histologic types (Table 2).
However, histologic grade, disease stage, and patient outcome
showed significant differences (P = 0.0004, P = 0.002, and
P = 0.0002 respectively). The mean MVD, as well as a high or low
MVD, did not differ significantly among benign, borderline, and
malignant ovarian tumours (Table 1). Likewise, no significant
correlation was found between MVD and the clinicopathologic
parameters in ovarian carcinomas (Table 2). Moreover, there was
no correlation between VEGF expression and MVD (Spearman
rank correlation coefficients: r = 0.0173, P = 0.892). We also
examined whether any correlation exists between the two parame-
ters within each set of histologic type of ovarian tumours and
failed to find a significant correlation (data not shown).
To investigate whether VEGF expression and MVD predict the
prognosis of patients with ovarian carcinomas, cumulative
survival curves for the 64 patients with ovarian carcinomas were
constructed according to the Kaplan–Meier method, and differ-
ences in survival were assessed with the log-rank test. The overall
5-year survival probability of the patients in our series was 66.4%
(Figure 3). The survival rate of patients with a high disease stage
(survivors, n = 15) or a high VEGF expression in the tumour
(survivors, n = 18) was significantly worse than that of patients
M 1 2 3456 VEGF
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Figure 2 VEGF mRNA expression in ovarian tissues showed four bands of
440, 572, 644, and 695 bps corresponding to VEGF isoforms of 121, 165,
189 and 206 respectively. M: molecular weight marker; Lane 1: normal ovary;
Lane 2: serous cystadenoma; Lanes 3 and 5: serous papillary
adenocarcinoma; Lane 4: poorly differentiated adenocarcinoma; Lane 6:
mucinous adenocarcinoma. Note that all tissues expressed VEGF mRNA
corresponding to the isoforms 121, 165, and 189.
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Figure 3 The overall survival curve of ovarian carcinoma patients showing
a 5-year survival time of 66.4%.
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Figure 4 Survival curves of ovarian carcinoma patients grouped according
to low (I–II) and high (III–IV) disease stages showing a significant difference
(P = 0.0004).
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Figure 5 Survival curves of ovarian carcinoma patients grouped
according to low and negative (scores 0–2) versus high (scores > 3)
VEGF expression showing a significant difference (P = 0.0004).with a low disease stage (survivors, n = 34) or a low or negative
VEGF expression (survivors, n = 31; P = 0.0004; Figure 4 and 5).
Further survival analysis of low-stage patients (n = 37) in relation
to VEGF expression did not show a significant difference, because
of the small number of events occurring in this subgroup. A high
or low MVD did not correlate with the survival time of patients
(Figure 6).
In a multivariate Cox proportional hazards regression analysis,
VEGF expression and disease stage were found to be significant
independent prognostic indicators of overall survival time
(P = 0.006 and P = 0.008, Table 3).
DISCUSSION
The current retrospective study established that both VEGF
expression and disease stage were independent significant prog-
nostic factors for predicting the survival of patients with ovarian
carcinomas. Overall immunoreactivity for VEGF was observed in
6% of benign cystadenomas, 69% of borderline tumours, and 96%
of carcinomas. The frequency of high VEGF expression was
significantly higher in carcinomas (48%) than that in benign (0%)
or borderline (15%) tumours (P = 0.0002 and P = 0.02 respec-
tively). Among the clinicopathologic parameters of ovarian carci-
noma, the degree of VEGF expression also correlated significantly
with the histologic grade, disease stage, and patient outcome.
Particularly, patients with high VEGF expression had poorer
survival times.
VEGF was first recognized as a vascular permeability factor
that induced tumour ascites and was active in increasing blood
vessel permeability, endothelial cell growth, and angiogenesis
(Senger et al, 1983; Leung et al, 1989). It was also described as
having a direct mitogenic action specific to vascular endothelial
cells (Keck et al, 1989). In ovarian carcinomas, the expression of
VEGF has been documented (Boocock et al, 1995; Abu-Jawdeh et
al, 1996). An increased VEGF mRNA or protein expression has
been correlated with a worse prognosis in patients with early and
advanced stage ovarian carcinomas (Paley et al, 1997; Hartenbach
et al, 1997). VEGF level has been shown to be elevated in cyst
fluid of ovarian malignancy (Hazelton et al, 1999) and in ascitis
fluid of a variety of malignancies (Kraft et al, 1999). Serum VEGF
level has also been reported to be elevated in ovarian carcinoma
patients (Kraft et al, 1999; Tempfer et al, 1998) and it was shown
to be an independent prognostic factor (Tempfer et al, 1998). As
our study was retrospective in nature, the serum VEGF values of
the patients had not been measured to allow correlation with the
immunohistochemical findings. In our study, immunostaining for
VEGF was largely restricted to the carcinoma cells, which is
consistent with the previous reports (Boocock et al, 1995; Abu-
Jawdeh et al, 1996) and support the observed increased serum
VEGF levels in ovarian cancer as well (Kraft et al, 1999; Tempfer
et al, 1998). We also observed VEGF immunostaining in the
luteinized theca-like cells in the subepithelial stroma, particularly
in mucinous cystadenomas. This finding is in accord with the
previous observation of strong VEGF expression in the luteinized
cells of developing follicles and corpora lutea (Kamat et al, 1995),
and accounts for a portion of VEGF production by the ovary in
health and disease. We did not observe a significant correlation
between VEGF expression and MVD in ovarian tumours. This
finding is consistent with the previous observations from a study
on a limited number of epithelial ovarian carcinomas showing that
a high VEGF expression was associated with a poor overall
survival, but no association was found between the VEGF expres-
sion and tumour MVD (Hartenbach et al, 1997). In one study, a
significant association was found between MVD and VEGF
expression in that the MVD of VEGF-rich tumours was signifi-
cantly higher than that of VEGF-poor tumours (Nakanishi et al,
1997). In contrast, another study of serous and mucinous ovarian
tumours suggested that VEGF may play a role in the control of
angiogenesis in serous and benign tumours, but it does not seem to
contribute to the higher MVD in mucinous tumours (Orre and
Ragers, 1999). Therefore, we also sought to determine whether
any correlation exists between VEGF expression and MVD within
each set of histologic type of ovarian tumours, but failed to iden-
tify a significant correlation. The lack of correlation between
VEGF expression and mean MVD observed in this study could be
explained by differences in methodologies used for the assessment
of VEGF and MVD. These include the use of serial tissue sections
and the equal size of the examined tumour area for determining the
expression level of VEGF and mean MVD employed in this study.
These factors were not taken into account in many other studies.
In our series, the mean MVD values in benign, borderline, and
malignant ovarian tumours were almost similar, and a high or low
MVD did not correlate with other clinicopathologic parameters of
ovarian carcinomas, including the survival time of patients (Table
2 and Figure 7). The prognostic independent influence of neovas-
cularization has been reported in several types of human solid
cancers (Weidner et al, 1996). In ovarian carcinomas, it has been
demonstrated that analysis of neovascularization in advanced 
stage ovarian cancer may be a useful prognostic factor
(Hollingsworth et al, 1995). However, recent results contradicted
VEGF and MVD in ovarian carcinoma 201
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Figure 6 Survival curves of ovarian carcinoma patients grouped according
to low (<32) and high (³32) microvessel density (MVD) showing no
significant difference (P = 0.84).
Table 3 Multivariate Cox proportional hazards regression analysis
Variable Wald chi-square P
Microvessel density (low vs high) 0.215 0.643
Histologic grade (1–2 vs 3) 2.261 0.132
Disease stage (I–II vs III–IV) 7.032 0.008
VEGF (low and negative vs high) 7.335 0.006the putative association between increased MVD and poor prog-
nosis in ovarian tumours (Orre et al, 1998). The result of our study
is in accord with this notion. These findings suggest that in ovarian
tumours, increased VEGF expression may not indicate an
enhanced angiogenesis, but it may reflect growth activity of the
tumour cells. In this context, a recent study by Garzetti et al
(1999b) has shown a correlation between VEGF expression and
MIB1 index, which is an important proliferative marker.
Several different isoforms of VEGF have been described that
result from alternative splicing of its mRNA. To assess whether
differential regulation of VEGF isoforms by ovarian carcinoma
could account for its increased secretion, RT-PCR analysis was
employed to find out which isoforms were expressed specifically
in normal, benign, and malignant ovarian tissues. We found VEGF
121, 165, and 189 to be uniformly expressed in all ovarian tissues
with the predominant isoforms being 165 and 121; and that the
isoform 206 was occasionally lacking. The relative abundance of
the different isoforms did not alter appreciably among different
histologic types, or among normal, benign, and malignant ovarian
tissues. Although many cases need to be examined before drawing
any conclusion, our results on the small number of tissues exam-
ined is at least consistent with the results of VEGF mRNA isoform
expression in a previous study of ovarian carcinoma cell lines
(Boocock et al, 1995) and a recent study of normal ovary and
ovarian carcinomas of various histologic types which showed the
isoforms 165 and 121 to be predominant regardless of the histo-
logic type and disease stage (Fujimoto et al, 1998).
In conclusion, our study signifies the prognostic value of VEGF
expression in ovarian carcinoma, and suggests that in conjunction
with the established clinicopathologic prognostic parameters,
VEGF expression may help to more accurately predict patients at
high risk for tumour progression who are potential candidates for
aggressive therapy. The significance of high VEGF expression
may be more applicable in patients with low-stage disease, since
low-stage patients with high VEGF expression may benefit from
additional therapy. This speculation awaits further studies and
approval. Finally, prospective studies are warranted to establish
the role of VEGF expression as a prognostic marker in ovarian
carcinoma.
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